True Wealth Design’s Acadia Pharmaceuticals ACAD Stock Holding History

True Wealth Design’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19K	Hold	47	–	–	﹤0.01%	1914
2026 Q1	$1.05K	Sell	47 -47	-50%	-$1.12K	﹤0.01%	1790
2025 Q4	$2.51K	Sell	94 -43	-31%	-$1.03K	﹤0.01%	1366
2025 Q3	$2.92K	Buy	137 +43	+46%	+$1.02K	﹤0.01%	1320
2025 Q2	$2.03K	Sell	94 -68	-42%	-$1.26K	﹤0.01%	1179
2025 Q1	$2.69K	Buy	162 +100	+161%	+$1.82K	﹤0.01%	904
2024 Q4	$1.14K	Buy	+62	New	+$1K	﹤0.01%	897

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

True Wealth Design's ACAD Position: Q2 2026 in Review

True Wealth Design held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 47 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #1914.

True Wealth Design first reported a position in ACAD in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.92K in Q3 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

True Wealth Design held 47 shares of Acadia Pharmaceuticals worth $1.19K as of Q2 2026.
True Wealth Design left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1914 holding.
True Wealth Design first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
True Wealth Design's Acadia Pharmaceuticals position peaked at $2.92K in Q3 2025.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.